<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898755</url>
  </required_header>
  <id_info>
    <org_study_id>ABTR04B1</org_study_id>
    <secondary_id>COG-ABTR04B1</secondary_id>
    <secondary_id>NCI-2009-00326</secondary_id>
    <nct_id>NCT00898755</nct_id>
  </id_info>
  <brief_title>Collecting and Storing Tissue From Young Patients With Cancer</brief_title>
  <official_title>Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of tissue, blood, and bone marrow from patients
      with cancer to study in the laboratory may help doctors learn more about changes that may
      occur in DNA and identify biomarkers related to cancer.

      PURPOSE: This laboratory study is collecting and storing tissue, blood, and bone marrow
      samples from young patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Establish and bank cell lines and/or xenografts from pediatric patients with cancer.

        -  Establish continuous cell lines, under carefully controlled conditions, from pediatric
           patients with cancer.

        -  Establish transplantable xenografts in immunocompromised mice from tumor cells that are
           difficult to establish as continuous cell lines in vitro.

        -  Create a bank of cell lines and generate sufficient vials of cryopreserved cells for
           distribution to investigators with approved COG biology protocols.

        -  Characterize cell lines from childhood cancers with respect to DNA short tandem repeat
           molecular profile as a &quot;fingerprint&quot; of original cell line identity.

        -  Characterize cell lines for the ability for sustained growth in tissue culture and/or as
           mouse xenografts.

        -  Characterize cell lines for mycoplasma contamination.

        -  Characterize cell lines for expression of molecular makers that confirm the tumor-type
           of the cell line and the immortal nature of the cells (telomerase) and the expression of
           molecular markers that may correlate with drug resistance.

      OUTLINE: This is a multicenter study. Specimens are stratified according to disease (acute
      lymphoblastic leukemia vs acute myeloid leukemia vs lymphoma vs osteogenic sarcoma vs Ewing
      family of tumors vs rhabdomyosarcoma vs primitive neuroectodermal tumor vs glioma vs
      astrocytoma vs rhabdoid tumors vs hepatoblastoma vs retinoblastoma vs Wilms tumor vs germ
      cell tumors vs other diagnoses).

      Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood
      and/or bone marrow are also collected and banked.

      Cell lines are established and characterized via reverse-transcriptase polymerase chain
      reaction and/or flow cytometry for biomarkers and by DNA fingerprinting.

      Markers to be identified may include the following:

        -  Neuroblastoma: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I,
           and HSAN 1.2 antigens

        -  Ewing family of tumors: EWS-FLI1, EWS-ERG, and PGP 9.5

        -  Retinoblastoma: interphotoreceptor retinoid-binding protein

        -  Acute lymphoblastic leukemia: immunophenotype

        -  Alveolar rhabdomyosarcoma: PAX3-FKHR, PAX7-FKHR, and MyoD1

        -  All cell types: telomerase expression including hTR and hTERT Mutations of TP53 gene are
           detected by flow cytometry and/or immunocytochemistry.

      No results of these tests are provided to the patient, the patient's physician, or the
      patient's medical records.

      PROJECTED ACCRUAL: A total of 500 specimens per stratum will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishment and banking of cell lines and/or xenografts from pediatric patients with cancer</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establishment of continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Establishment of transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Creation of a bank of cell lines and generation of sufficient vials of cryopreserved cells for distribution to investigators with approved COG biology protocols</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of cell lines from childhood cancers with respect to DNA PCR molecular HLA profile as a &quot;fingerprint&quot; of original cell line identity</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of cell lines for the ability for sustained growth in tissue culture and/or as mouse xenografts</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of cell lines for mycoplasma contamination</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterization of cell lines for expression of molecular makers that confirm the tumor-type of the cell line and the immortal nature of the cells (telomerase) and the expression of molecular markers that may correlate with drug resistance</measure>
    <time_frame>length of study</time_frame>
  </primary_outcome>
  <number_of_groups>17</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNET (central)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glioma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astrocytoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Diagnoses</arm_group_label>
    <description>Sample of blood, bone marrow, or of the tumor is removed for evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>PNET (central)</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>Astrocytoma</arm_group_label>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <arm_group_label>Other Diagnoses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>PNET (central)</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>Astrocytoma</arm_group_label>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <arm_group_label>Other Diagnoses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>PNET (central)</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>Astrocytoma</arm_group_label>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <arm_group_label>Other Diagnoses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>PNET (central)</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>Astrocytoma</arm_group_label>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <arm_group_label>Other Diagnoses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Acute Lymphoblastic Leukemia (ALL)</arm_group_label>
    <arm_group_label>Acute Myelogenous Leukemia (AML)</arm_group_label>
    <arm_group_label>Lymphoma</arm_group_label>
    <arm_group_label>Osteogenic sarcoma</arm_group_label>
    <arm_group_label>Ewing's family tumors (ESFT)</arm_group_label>
    <arm_group_label>Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>PNET (central)</arm_group_label>
    <arm_group_label>Glioma</arm_group_label>
    <arm_group_label>Astrocytoma</arm_group_label>
    <arm_group_label>Rhabdoid tumors</arm_group_label>
    <arm_group_label>Retinoblastoma</arm_group_label>
    <arm_group_label>Wilm's tumor</arm_group_label>
    <arm_group_label>Neuroblastoma (Patients not eligible for ANBL00B1)</arm_group_label>
    <arm_group_label>Diagnosis Pending (for presumed relapsed patients)</arm_group_label>
    <arm_group_label>Germ Cell Tumors</arm_group_label>
    <arm_group_label>Hepatoblastoma</arm_group_label>
    <arm_group_label>Other Diagnoses</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient that has been enrolled on a COG therapeutic, biology, or tissue banking
        protocol that allows collection of tissue for research and submission to a COG-designated
        resource laboratory is eligible for this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  All malignant tissues from childhood cancers allowed including the following:

               -  Brain tumors (all types)

                    -  Tissue should be submitted to CNS Committee Resource labs to be forwarded
                       for this study, unless instructed otherwise on the COG web site

               -  Ewing family of tumors

               -  Rhabdomyosarcomas

               -  Other soft tissue sarcomas

               -  Osteogenic sarcomas

               -  Rhabdoid tumors

               -  Neuroblastomas

                    -  Viable material for cell culture for neuroblastoma is collected via
                       COG-ANBL00B1 and should not be submitted via this study unless the patient
                       cannot be enrolled on COG-ANBL00B1* NOTE: *The same applies to any similar
                       biology studies from other disease committees

               -  Retinoblastomas

               -  Anaplastic Wilms tumor

               -  Germ cell tumors

               -  Leukemias/lymphomas

                    -  Acute myeloid leukemia (AML)

                         -  Blood samples and bone marrow samples from patients at second relapse
                            and beyond may be submitted for this study

                         -  Bone marrow samples at diagnosis or first relapse must be submitted to
                            an AML resource lab and will be forwarded for this study at the
                            discretion of the AML Committee

                    -  Acute lymphoblastic leukemia (ALL)

                         -  Blood samples may be submitted directly to this study

                         -  Bone marrow samples must be submitted to an ALL resource lab and will
                            be forwarded for this study at the discretion of the ALL Committee

          -  Enrolled on a COG therapeutic, biology, or tissue banking protocol that allows
             collection of tissue for research and submission to a COG-designated resource
             laboratory

               -  Participation in this protocol is not permitted until after tissue requirements
                  for any active COG disease-specific therapeutic, biology, or banking protocols
                  have been satisfied

               -  Material may only be submitted for this protocol if tissue is available in excess
                  of that required for satisfying active disease-specific therapeutic and
                  biological protocols

          -  Patients with diagnosis pending are eligible

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Patrick Reynolds, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry J. Maurer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama at University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph G. Pressey</last_name>
      <phone>205-939-9285</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - Arkansas Cancer Research Center at Uni</last_name>
      <phone>501-686-8274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - City of Hope Comprehensive Cancer Cen</last_name>
      <phone>800-826-4673</phone>
      <email>becomingapatient@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jonathan Jaques Children's Cancer Center at Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda M. Termuhlen</last_name>
      <phone>562-933-8605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert M. Cooper</last_name>
      <phone>323-783-5307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Presbyterian - St. Luke's Medical Cen</last_name>
      <phone>303-839-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Connecticut Children's Medical Center</last_name>
      <phone>860-545-9967</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lee Cancer Care of Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Lee Cancer Care of Lee Memorial Healt</last_name>
      <phone>877-680-0008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory A. Hale</last_name>
      <phone>727-767-4176</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Cancer Institute at St. Joseph's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - St. Joseph's Cancer Institute</last_name>
      <phone>800-882-4123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaplan Cancer Center at St. Mary's Medical Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narayana Gowda</last_name>
      <phone>561-844-6363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain States Tumor Institute at St. Luke's Regional Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712-6297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Chang</last_name>
      <phone>208-381-2731</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - University of Illinois Cancer Center</last_name>
      <phone>312-355-3046</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Midwest Affiliate</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A. De Alarcon</last_name>
      <phone>309-655-4242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simmons Cooper Cancer Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62794-9677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Simmons Cooper Cancer Institute</last_name>
      <phone>217-545-7929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Markey Cancer Center at University of</last_name>
      <phone>859-257-3379</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Kosair Children's Hospital</last_name>
      <phone>502-629-5500</phone>
      <email>CancerResource@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Office of Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71315-3198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Tulane Cancer Center</last_name>
      <phone>504-988-6121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute at Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajasekharan (Raj) P. Warrier</last_name>
      <phone>504-842-5230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alvin and Lois Lapidus Cancer Institute at Sinai Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M. Wiley</last_name>
      <phone>410-601-6266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-5381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Lobel</last_name>
      <phone>269-341-6350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Office - Ellis Fischel Cancer Center</last_name>
      <phone>573-882-7440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxine L. Hetherington</last_name>
      <phone>816-234-3265</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-2306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Bernstein</last_name>
      <phone>702-732-1493</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Hackensack University Medical Center</last_name>
      <phone>201-996-2879</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carol G. Simon Cancer Center at Morristown Memorial Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven L. Halpern</last_name>
      <phone>973-971-6720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Herbert Irving Comprehensive Cancer C</last_name>
      <phone>212-305-8615</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Blumenthal Cancer Center at Carolinas</last_name>
      <phone>704-355-2884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Wake Forest University Comprehensive</last_name>
      <phone>336-713-6771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308-1062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Akron Children's Hospital</last_name>
      <phone>330-543-3193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousif (Joe) H. Matloub</last_name>
      <phone>216-844-3345</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente</last_name>
      <phone>866-223-8100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tod Children's Hospital</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Tod Children's Hospital</last_name>
      <phone>330-884-3955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Y. McNall-Knapp</last_name>
      <phone>405-271-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Children's Hospital of Pittsburgh</last_name>
      <phone>412-692-7056</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole L. Bryant</last_name>
      <phone>864-455-8898</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Tennessee Children's Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray C. Pais</last_name>
      <phone>865-541-8266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center School of Medicine - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osvaldo Regueira</last_name>
      <phone>806-354-5434</phone>
      <phone_ext>282</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Driscoll Children's Hospital</last_name>
      <phone>361-694-5311</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latha Prasannan</last_name>
      <phone>806-725-4840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3993</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Estrada</last_name>
      <phone>210-575-7268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della L. Howell</last_name>
      <phone>210-916-7727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caron Strahlendorf</last_name>
      <phone>604-875-3576</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvan Samson</last_name>
      <phone>514-345-4931x2790</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood extragonadal germ cell tumor</keyword>
  <keyword>childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood teratoma</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage I childhood liver cancer</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood hepatoblastoma</keyword>
  <keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>localized Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>childhood hepatocellular carcinoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood Langerhans cell histiocytosis</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>childhood germ cell tumor</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>localized osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>extraocular retinoblastoma</keyword>
  <keyword>intraocular retinoblastoma</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>stage I Wilms tumor</keyword>
  <keyword>stage II Wilms tumor</keyword>
  <keyword>stage III Wilms tumor</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>stage II childhood liver cancer</keyword>
  <keyword>stage III childhood liver cancer</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <keyword>unusual cancers of childhood</keyword>
  <keyword>stage V Wilms tumor</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>rhabdoid tumor of the kidney</keyword>
  <keyword>childhood extracranial germ cell tumor</keyword>
  <keyword>childhood central nervous system choriocarcinoma</keyword>
  <keyword>childhood central nervous system embryonal tumor</keyword>
  <keyword>recurrent childhood central nervous system embryonal tumor</keyword>
  <keyword>childhood central nervous system germinoma</keyword>
  <keyword>childhood central nervous system mixed germ cell tumor</keyword>
  <keyword>childhood central nervous system teratoma</keyword>
  <keyword>childhood central nervous system yolk sac tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

